大阪府立呼吸器・アレルギー医療センターの多剤耐性結核患者の動向と関西地区の多剤耐性結核患者アンケート調査、ならびに近畿中央胸部疾患センターの現入院患者の実態

研究分担者　松本智成　大阪府結核予防会大阪病院診断検査部　部長
研究協力者　永井崇之　大阪府立呼吸器・アレルギー医療センター感染症内科　部長
研究協力者　露口一成　近畿中央胸部疾患センター臨床研究センター　部長

研究要旨

　2011年9月14日には世界保健機関（ＷＨＯ）が、従来の薬が効かない MDR-TB や XDR-TB の感染が欧州・中央アジア地域で急速に拡大しており、保健当局が阻止できなければ多くの死者が出ると警告した。このため新薬開発ならびに結核ワクチンの開発は重要である。特にワクチンの場合は耐性誘導の問題がなく MDR-/XDR-TB 対策には重要である。岡田等は DNA ワクチンを開発し in vitro ならびに霊長類にたいする in vivo の研究で期待のできる結果を報告している。ヒト投与への前段階として関西圏における多剤耐性結核患者の患者数調査の準備を行った。

　多剤耐性結核（MultiDrug Resistant-Tuberculosis: MDR-TB）は、結核治療の要であるイスコチンとリファンピシンの少なくとも 2 剤の抗結核薬に耐性の結核菌の総称である。そして超多剤耐性結核(XDR-TB)とは、さらにニューキノロン系の薬剤とアミノグリコシド系の薬剤に耐性の結核菌であると定義される。米国の医学雑誌 New England Journal of Medicine (NEJM)によると現在、世界における感染症による死因の一位は、呼吸器感染症。二位、消化器感染症、三位 HIV 感染症。四位結核となっている。

　2009 年の WHO の推計では、世界中で年間 940 万人が新規に結核を発病し、そのうち 130 万人が死亡している。最近は減少傾向に転じたが、かつては人類史上減った事が無い病気といわれていた。特にアジア、アフリカでの増加が大きな要因であり、HIV/AIDS、多剤耐性結核(MDR-TB)と超耐性結核(XDR-TB)がその増加の一躍を担っている。HIV 合併結核、ならびに MDR-/XDR-TB はさらに結核の治療を質的にも難しくしている。にぶりながらも減少している日本での結核罹患率は、再び上昇するという不安材料もみられる。それは合衆国で 1980 年代半ばから 1990 年代初頭にみられた結核の再流行時と、現在の日本の状況が酷似しているからである。

　当時の米国の状況は、
- 結核コントロールの主要機関への投資の減少
- HIV/AIDS の流行
- 国際化による結核蔓延地からの米国への流入増加
- ホームレスシェルターや老人ホーム等での集団感染

- 不況による受診の遅れ
- 多剤耐性結核の出現

以上のとおりであったが、現在の日本の状況に非常に良く似ている。アジア、アフリカ、ヨーロッパで増加し、治療難易度が高い HIV 合併結核 MDR-/XDR-TB が日本では減っていくのであろうか？未だかつて減少した事が無い感染症であること、海外の状況、前述した日本の状況も加味して考えると結核は再び増加する可能性があるといえる。

また、2011 年 9 月 14 日には世界保健機関（WHO）が、従来の薬が効かない MDR-TB や XDR-TB の感染が欧州・中央アジア地域で急速に拡大しており、保健当局が阻止できなければ多くの死者が出ると警告した。WHO は多剤耐性結核菌患者の死亡率が 50%に達すると指摘、患者数は欧州 27 カ国のうち上位 15 カ国が東欧に集中しアジアでも患者数が増加していると報告した。新たに結核と診断された患者の約 12%が多剤耐性結核菌の感染者であるのに対し、結核再発と診断された患者の場合は 37%に達したという。その一方で、ロンドンに限定すれば毎年 3500 人が多剤耐性結核菌に感染し、西欧の都市では最多という。

主軸の薬である INH と RFP に同時に効かない MDR-/XDR-TB の治療はとても困難になる。治療には副作用の強い薬を何種類も、長期にわたって服用し、可能であれば手術をも行うが成績はあまりよくなく、図に見られるように、治癒が確認されたのは 62%であり、残りは死亡するか排菌要陽性が続いたままである。

このため MDR-/XDR-TB の治療に対して岡田等が作成した DNA ワクチンが期待されている。

A．研究目的

MDR-/XDR-TB に対する DNA ワクチン投与前の調査として関西における多剤耐性結核の概数を調査する。

B．研究方法

関西における MDR-/XDR-TB の動向を結核病棟を有する病院へのアンケート調査をする為のアンケート用紙を作成する。

前調査として 2000 年からの大阪府立呼吸器・アレルギー医療センターにおける MDR-TB 排菌患者のべ数を調べる。

前調査として 2004 年からの大阪府立呼吸器・アレルギー医療センターにおける新規 MDR-TB 排菌患者数を調べた。

C．研究結果

アンケートを作成（年齢、性別、罹病期間、薬剤感受性、手術歴、排菌陰性化の有無、入院年数）を行い関西圏の結核病棟を有する病院に依頼する。初年度は、近畿中央胸部疾患センター、大阪府立呼吸器・アレルギー医療センター、結核予防会大阪病院に関して行った。

2000-2001 年には 45 人を上回っていた大阪府立呼吸器・アレルギー医療センターの多剤耐性結核排菌のべ患者数は徐々に減少し 2011 年には 15 人になった。

2004 年から 2009 年まで大阪府立

呼吸器・アレルギー医療センターの新規 MDR-TB 患者数をみると 13 名から 5 名へ減少。XDR-TB 患者数は、2004 年が 7 名で、2008 年は 1 名、2009 年は 0 と減少した。

　また、DNA ワクチン投与対象患者は、大阪府結核予防会大阪病院では 0 であったが、大阪府立呼吸器・アレルギー医療センターにおいては結核診断から 15 年以上たった ADL 良好な XDR-TB 患者を少なくとも 1 名確認出来た。

D. 考察

　少なくとも我々が今回調べた新規 MDR-/XDR-TB 患者数は 10 年前と比較すると減少傾向にあり DOTS の普及および結核感染対策が功をなしたと考えられる。しかしながら結核歴が 15 年以上の慢性持続排菌患者も存在しており岡田等が開発した DNA ワクチンへの期待が持たれる。

E. 結論

　少なくとも我々が今回調べた新規 MDR-/XDR-TB 患者数は 10 年前と比較すると減少傾向にある。しかしながら結核歴が 15 年以上の慢性持続排菌患者も存在しており岡田等が開発した DNA ワクチンへの期待が持たれる。

F. 健康危険情報
　特になし

G. 研究発表
1. 論文発表
1. Tomoshige Matsumoto, Hideo Ogata, Emiko Toyota, Katsuhiro Suzuki, Takefumi Saito, Akira Fujita, Toshinori Suetake, Kinuyo Chikamatsu, Kazue Mizuno, Satoshi Mitarai：Clinical evaluation of a line probe assay kit for the identification of mycobacterium species and detection of drug-resistant mycobacterium tuberculosis Kekkaku: [Tuberculosis] 03/2013; 88:291-296.

2. 松本智成：IGRA による結核診断. 日本内科学会雑誌 11 月号 in press

3. 松本智成：結核－古くて新しい感染症－結核菌の分子疫学の展開. 最新医学, 68 巻 11 月, p2496-2502, 2013

4. 松本智成：多剤耐性結核の現状呼吸. 32(8): 697-702, 2013

2. 学会発表
1. 松本智成, 永井崇之, 田村嘉孝, 黒川雅史, 川瀬一郎, 藤井隆, 相良憲幸：QIAxcel^{TM} Advanced System を使用した結核菌 Supply's 15-MIRU VNTR 解析. 第 89 回日本結核病学会総会

H. 知的財産権の出願・登録状況
1. 特許取得
2. 実用新案登録
3. その他

多剤耐性結核に対する新規治療用DNAワクチンの開発・実用化に関する研究

研究分担者　熊ノ郷　淳　大阪大学　教授

研究要旨
　本研究は、新規ワクチン（HVJ－エンベロープ/HSP65 DNA＋IL－12 DNA）の第1相を実施し、本ワクチンの薬事法に基づく承認取得を目指しているが、本分担研究では、近畿地区の結核診療施設の結核患者の臨床試験統括。結核ワクチンの薬効解析基盤の確立を行った。

A．研究目的

　新規ワクチン（HVJ－エンベロープ/HSP6DNA＋IL－12 DNA）の有効性。安全性を確認するため、多剤耐性結核に対する医師主導治験（第1相）を実施し、本ワクチンの薬事法に基づく承認取得を目的としている。

B．研究方法と C．研究結果

　本分担研究では、近畿地区の結核診療施設の結核患者の臨床試験統括。結核ワクチンの薬効解析基盤の確立に着手した。マウスを用いた細胞性免疫、液性免疫双方の測定基盤の立ち上げ。関連施設連携を行った。

D．考察

E．結論

F．健康危険情報
　なし

G．研究発表
1．論文発表
1．Kumanogoh A and Kikutani H.: Immunological functions of the neuropilins and plexins as receptors for semaphorin. Nature Review Immunology. Nature Reviews Immunolog 13:802. 2013.

2．学会発表
　なし

H．知的財産権の出願・登録状況
1．特許取得
　なし
2．実用新案登録
　なし
3．その他
　なし

別紙4

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
岡田全司	結核予防（DNA）ワクチンの開発状況　予防接種Q&A 改訂3版	「小児内科」「小児外科」編集委員会共編	小児内科	東京医学社		2013	45（増刊号）281-283

雑誌

発表者 氏　名	論文タイトル名	発表誌名	巻号	ページ	出版年
岡田全司	The study of novel DNA vaccines against tuberculosis: Induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis.	Human Vaccines and Immunother-apeutics	9(3)	515-525	2013
岡田全司	Novel therapeutic vaccines [(HSP65+IL-12)DNA-, granulysin-and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy.	Human Vaccines and Immunother-apeutics	9(3)	526-533	2013
金田安史	Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application.	Cancer Gene Ther	20	599-605	2013
金田安史	Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma.	Clinical Immunology	149	1-10	2013
松本智成	Clinical evaluation of a line probe assay kit for the identification of mycobacterium species and detection of drug-resistant mycobacterium tuberculosis.	Kekkaku [Tuberculosis]	88	291-296	2013
熊ノ郷淳	Immunological functions of the neuropilins and plexins as receptors for semaphorin. Nature Review Immunology.	Nature Reviews Immunolog	13	802	2013
岡田全司	結核におけるワクチンへの期待"次世代型感染症ワクチン"	最新医学		出版中	
岡田全司	結核の免疫反応「免疫学的機序からみた呼吸器疾患」	日本胸部臨床	72(12)	1336-1345	2013

岡田全司	はじめに（序論）「結核―古くて新しい感染症―」	最新医学	68(11)	2437-2438	2013
岡田全司	座談会：結核の現状・問題点と最新の知見	最新医学	68(11)	2439-2450	2013
岡田全司	ヒト結核感染に最も近いカニクイザルを用いた新規結核予防ワクチン開発及び臨床応用に向けて　「結核―古くて新しい感染症―」	最新医学	68(11)	2479-2487	2013
岡田全司	多剤耐性結核治療ワクチンとT細胞免疫	最新医学	68(11)	2488-2495	2013
松本智成	IGRA による結核診断	日本内科学会雑誌			2014 in press
松本智成	結核―古くて新しい感染症―結核菌の分子疫学の展開	最新医学	68	2496-2502	2013
松本智成	多剤耐性結核の現状呼吸		32(8)	697-702	2013

添付資料

Novel therapeutic vaccines [(HSP65 + IL-12) DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy

Yoko Kita,[1] Satomi Hashimoto,[1] Toshihiro Nakajima,[2] Hitoshi Nakatani,[1] Shiho Nishimatsu,[1] Yasuko Nishida,[1] Noriko Kanamaru,[1] Yasuhumi Kaneda,[3] Yasushi Takamori,[4] David McMurray,[5] Esterlina V. Tan,[6] Marjorie L. Cang,[6] Paul Saunderson,[6] E.C. Dela Cruz[6] and Masaji Okada[1,*]

[1]Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan; [2]Ikeda Laboratory; GenomIdea Inc.; Midorigaoka, Ikeda; [3]Division of Gene Therapy Science; Graduate School of Medicine; Osaka University; Suita, Osaka Japan; [4]Department of Periodontology; Tsurumi University School of Dental Medicine; Tsurumi, Tsurumiku Japan; [5]Texas A&M University; System Health Center; College of Medicine; College Station, TX USA; [6]Leonard Wood Memorial Institute; Cebu, Philippines

Purpose: Multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant (XDR) TB are big problems in the world. We have developed novel TB therapeutic vaccines, HVJ-Envelope/HSP65 + IL-12 DNA vaccine (HSP65-vaccine), granulysin vaccine and killer specific secretory protein of 37kDa (Ksp37) vaccine.

Results and Methods: HSP65 vaccine showed strong therapeutic effect against both MDR-TB and XDR-TB in mice. Intradermal immunization of HSP65-vaccine showed stronger therapeutic effect against TB than intramuscular or subcutaneous immunization. Furthermore, the synergistic therapeutic effect was observed when the vaccine was administrated in combination with Isoniazid (INH), which is a first line drug for chemotherapy. The combination of types of vaccines (HSP65- and granulysin- vaccines) also showed synergistic therapeutic effect. In the monkey model, granulysin-vaccine prolonged the survival period after the infection of TB and long-term survival was observed in vaccine-treated group. We examined the potential of two kinds of novel DNA vaccines (Ksp37-vaccine and granulysin-vaccine). Both vaccines augmented in vivo differentiation of CTL against TB. We measured the amount of Ksp37 protein in human serum and revealed that the level of Ksp37 protein of patients with tuberculosis was lower than that of healthy volunteers. Therefore, we established Ksp37 transgenic mice as well as granulysin transgenic mice to elucidate the function of those proteins. Both transgenic mice were resistant to TB infection.

Conclusion: These data indicate the potential of combinational therapy; the combination of two DNA vaccines or combination of DNA vaccine with antibiotic drug. Thus, it will provide a novel strategy for the treatment of MDR-TB.

Introduction

Tuberculosis is a major global threat to human health, with about 2 million people dying every year from Mycobacterium tuberculosis (TB) infection. The only tuberculosis vaccine currently available is an attenuated strain of Mycobacterium bovis BCG (BCG), although its efficacy against adult TB disease remains controversial. Furthermore, multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant TB (XDR-TB) are becoming big problems in the world. About 500,000 of people around the world are affected by MDR-TB every year. However, there are a small number of effective drugs against MDR-TB. In such circumstances, the development of therapeutic as well as prophylactic vaccines against TB is required.

Cynomolgus monkey model is the best animal TB model to evaluate the potential of newly developed vaccines as reported by Walsh and Tan.[1] Onset and progress after TB infection in the cynomolgus monkey is very similar to human TB disease.[1-3] SCID-PBL/hu is an IL-2 receptor γ-chain disrupted mouse (NOD-SCID) transplanted with human PBL. It is an in vivo humanized immune model and provides an useful tool for investigating human immune responses to the administration

Table 1. Therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine on TB infection in murine models

1) HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine showed therapeutic efficacy against MDR-TB as well as drug-sensitive TB in mice.

2) Significant prolongation of survival was observed in the XDR-TB infected mice by the treatment with this vaccine.

3) Therapeutic efficacy of this vaccine on chronic TB disease models using a mouse infected with TB in the aerosol chamber was demonstrated.

Therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine was evaluated by using mouse models. Therapeutic efficacies of this vaccine on the MDR-TB infection and XDR-TB infection were observed.

of vaccines.[4,5] Transgenic mice that express the components of vaccine also provide a lot of information about novel TB vaccines. Therefore, we used three animal models (cynomolgus monkey model of TB, SCID-PBL/hu mice and transgenic mice) to develop three kinds of novel vaccines against TB.

We have previously evaluated a novel therapeutic TB vaccine which consists of plasmid DNA encoding HSP65 + IL-12 and HVJ-Envelope (HSP65-vaccine) and revealed the efficacy of the vaccine in these animal models.[6-9] However, it is very important to treat the patients with TB completely within a short period of time. Therefore, we improved the regimen of the vaccination. We first examined a combination therapy of vaccination and chemotherapy. In the present study, we used a HSP65-vaccine for the vaccination and first line TB drugs (INH or RFP) for the chemotherapy. We next identified a suitable administration route to increase the efficacy of the DNA vaccine. The result suggested that intradermal vaccination is more suitable for the DNA vaccine than intramuscular or subcutaneous vaccination.

Finally, we developed plasmid-based DNA vaccines encoding the granulysin or Ksp37. Granulysin is a member of the saposin-like protein family and colocalizes with perforin and granzymes in the cytolytic granules of human CTL and NK cells. In the presence of perforin, it has a cytolytic activity against intracellular pathogens in the cytoplasm of infected cells. It also has a cytotoxic effect on tumor cells.[10-12] Granulysin is present in cytoplasm of human CD8 positive cytotoxic T cells and NK cells. It has been suggested that granulysin has a cytolytic activity against *M. tuberculosis* outside macrophages and reduces the number of *M. tuberculosis* in the macrophage dependent on the presence of perforin in vitro.[11] However, the precise role of granulysin in vivo has not been elucidated yet. Therefore, we have established granulysin transgenic mice to elucidate in vivo role of granulysin and obtain the information to develop novel vaccines against *M. tuberculosis*. Transgenic mice of 15K and 9K granulysins were resistant to TB infection in vivo. This is the first report indicating an in vivo role of granulysin in the defense against the infection of TB. In addition, we demonstrated the efficacy of granulysin-vaccine in the monkey model of TB.

Ksp37 is also produced from CTL and NK cells.[13] However, immunological function of Ksp37 has not been elucidated yet. In the first step, we first examined the amount of Ksp37 in the serum of patients with TB. The result indicated that Ksp37 in the serum of patients with TB was lower than that of healthy volunteer. In the next step, we have established Ksp37 transgenic mice to elucidate the in vivo role on Ksp37 in the immunity to the infection of *M. tuberculosis*. Ksp37 transgenic mouse was resistant to the infection of TB, suggesting the anti-TB effect of Ksp37 in vivo.

To increase the efficacy of the vaccine, we examined the synergistic effect of the combination therapy, in which HSP65-vaccine and first line chemotherapy drug (INH) were administrated. We also examined the synergistic effect of the combination of two kinds of DNA vaccines. HSP65- and granulysin-vaccine were simultaneously administrated in the murine models of TB and efficacy of the vaccines was evaluated in vivo.

In parallel, we investigated the immunological effects of granulysin and Ksp37 and revealed the synergistic effect of two molecules on the induction of TB-specific CTL (manuscript submitted).

These findings demonstrated that granulysin-vaccine and Ksp37-vaccine might provide very useful weapon as TB vaccines, and those efficacy will be enhanced in combination with other DNA vaccine (including HSP65 vaccine) and INH.

Results

Novel therapeutic vaccine of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine. *Therapeutic effect of the vaccine in murine models of TB.* Therapeutic efficacy of HSP65 DNA + IL-12 DNA vaccine (HSP65-vaccine) was evaluated in murine models. At 30 d after intravenous challenge of MDR-TB, the CFUs of TB in the lungs, spleen, and liver were counted and therapeutic efficacy of HVJ-Envelope DNA vaccine was evaluated.

Table 1 shows the feature of novel TB vaccines; the vaccine consists of a plasmid DNA vaccine expressing mycobacterial heat shock protein 65 (HSP65)+interleukin-12 (IL-12) and a vector (hemagglutinating virus of Japan (HVJ)-liposome or HVJ-envelope). We used the mouse model in our previous study.[6,7] This vaccine showed therapeutic effect against TB in the mouse: (1) This vaccine significantly decrease the number of drug sensitive H37Rv TB in the spleen and the lung of mice (data not shown). This vaccine also decreased the number of MDR-TB in the lungs and spleen of mice, indicating the efficacy of the vaccine in the mouse model of TB. (2) Significant prolongation of survival was observed in the XDR-TB infected mice. The survival period of the mouse treated with this vaccine was prolonged compared with non-vaccinated mice. Those results demonstrated that this vaccine have strong therapeutic effect against XDR-TB. (3) We have established the mouse model of chronic TB disease using an inhalation system (aerosol chamber) for the infection of TB. By using this model, therapeutic efficacy of this vaccine was examined. The vaccine was administered 5 weeks after aerosol infection of TB. Treatment with this vaccine decreased the number of TB in the lung of the mice (data not shown).

Thus, we demonstrated that this vaccine had a therapeutic effect against XDR-TB and MDR-TB as well as drug-sensitive TB.

Synergistic effect of HVJ-Envelop/HSP65 DNA + IL-12 DNA vaccine in combination with INH against TB infection. To enhance the

Figure 1. Synergistic therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine and INH on TB infection of mice. BALB/c mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber. One week after challenge of TB, the vaccine and INH (0.03mg/mouse) were administered 6 times for 3 weeks. Five weeks after TB challenge, mice were sacrified, and CFU of TB in the spleen were evaluated. G1 vs. G2; p < 0.05; G1 vs. G3; p < 0.05; G3 vs. G5; p < 0.05; G2 vs. G5 p < 0.05; Student's test.

Figure 2. Synergistic therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine and INH on TB infection of mice. BALB/c mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber. One week after challenge of TB, the vaccine and INH (0.03mg/mouse) were administered 6 times for 3 weeks. Five weeks after TB challenge, mice were sacrified, and CFU of TB in the liver were evaluated. G2 vs. G4; p < 0.05; G3 vs. G4; p < 0.05; Student's test.

efficacy, we examined synergistic effect of combinational therapy of this vaccine and INH (isoniazid) on the infection of TB. The numbers of TB in the mouse spleen and liver were significantly decreased compared with the monotherapy; indicating the synergistic effect of the combinational therapy (Figs. 1 and 2).

We also compared the administration route of the vaccine to improve the regimen of the therapy. We selected three routes (intradermal, intramuscular and subcutaneous injections) for our experiment. The efficacy of intradermal administration (i.d.) was highest among three administration routes (Fig. 3).

Therefore, in the monkey model we plan to study the efficacy of intradermal injection of this vaccine, in comparison to i.m administration.

IL-2 receptor γ-chain gene disrupted SCID-PBL/hu. We have very important humanized immune model (SCID-PBL/hu) to study the human T cell immune response in vivo as reported first in Cancer Research 1997.[4] We evaluated the efficacy of novel vaccines in vivo using this humanized immune model.

We used IL-2 receptor γ-chain gene knockout mouse-based model (NOD SCID-PBL/hu) to analyze the human T cell responses to the vaccine (Table 2).

The efficacy of HSP65+ IL-12 DNA vaccine was examined in this IL-2 receptor γ-chain gene disrupted SCID-PBL/hu-model and significant decrease of the number of TB in the liver was observed as shown in Table 2A. This model shows stronger human CTL induction and proliferation than conventional SCID mouse-based model (CB17-SCID-PBL-hu) (Table 2B).

Therapeutic efficacy of this vaccine on monkey model. We are developing a GMP level of DNA vaccine that contains two expression units in one plasmid vector for future clinical trial. In this study, we used a GMP level of DNA vaccine for the evaluation of the potency in the monkey model of TB. Monkeys were intratracheally instillated with 5×10^2 CFU of human TB (Erdman strain). After TB infection, 9 times intramuscular injection of this vaccine (total 400 μg/monkey) was conducted. Therapeutic efficacy was evaluated on the basis of survival, ESR, body weight, immune responses, chest X-ray and PPD skin test. The monkey group treated with HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine showed 100% survival (data not shown). In contrast, the monkey group of control saline showed 60% survival. Thus, the therapeutic DNA vaccine improved the survival rate of TB-infected monkeys, compared with the saline (control).

These data indicated the therapeutic efficacy of a GMP-level of DNA vaccine in TB-infected monkeys.

Efficacy of granulysin-vaccines. *Efficacy of granulysin in transgenic mice.* We noticed the in vivo function of granulysin, since it shows a cytolytic activity against Mycobacterium tuberculosis. The features of granulysin are as follows:

(1) Granulysin is cytolytic molecules expressed by human CTL and NK cells and show the cytolytic activity against a variety of tumors and microbes, including Mycobacterium tuberculosis. Granulysin belongs to the saposin-like protein family that includes amoebapores and NK lysine. Recent studies show that granulysin also has chemoattractant and proinflammatory activities. However, in vivo anti-microbe activity and anti-tuberculosis activity of granulysin has not been elucidated yet.

(2) It has been reported that the granulysin has the function of in vitro cytotoxic activity against *M. tuberculosis* outside the macrophage cells, and contributes the in vitro reduction of *M. tuberculosis* in the macrophage in the presence of perforin.

(3) However, the precise role of granulysin in the in vivo against the tuberculosis infection has not been elucidated yet. Therefore, we have established granulysin transgenic mice to elucidate mechanism of granulysin in vivo. We have established two kinds of transgenic mice by using usual microinjection method: 15K granulysin transgenic mice and 9K granulysin transgenic

Figure 3. Therapeutic efficacy of intradermal (i.d.) vaccination of HVJ-Envelope/HSP65 DNA + IL-12 DNA, compared with intramuscular (i.m.) or subcutaneous (s.c.) vaccination using intratracheally aerosol infected DBA/1 mice. DBA/1 mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber. One week after challenge of TB, 100 μg of HVJ-Envelope/HSP65 DNA + IL-12 DNA were administered 6 times for 3 weeks by i.d, i.m, or s.c administration. Four weeks after TB challenge, mice were sacrified, and CFUs of TB in the spleen were evaluated. G1 vs. G2; $p < 0.05$; G1 vs. G3; $p < 0.05$; Student's test.


Figure 4. The establishments of 15K granulysin transgenic mice and 9K granulysin transgenic mice. The efficacies of 15K granulysin transgenic mice and 9K granulysin transgenic mice on TB infection were summarized in this Figure. An anti-TB effect, the induction of CTL against TB, the proliferation of T cells against TB and γ-IFN production were augmented in these transgenic mice, compared with wild type C57BL/6 mice.

As summarized in **Figure 4**, augmentation of immune responses were also observed in 15K granulysin transgenic mice: in vivo induction of cytotoxic T cells against TB, enhanced proliferation of T cells stimulated with TB antigen and augmentation of cytokine production. Furthermore, we examined synergistic effects of the combination of two vaccines. As shown in **Figure 5**, the combination of HSP65-vaccine and granulysin-vaccine showed synergistic effects and 10 times reduction of the CFU number in the liver of TB-infected mice was observed. The number of TB in the liver was significantly reduced by the combination of two vaccines.

Efficacy of granulysin-vaccine in monkey models. We examined the efficacy of granulysin-vaccine in the therapeutic model of TB. The survival rate of granulysin-vaccine (HVJ-Envelope/15K granulysin DNA vaccine)-treated group was 25% (1/4) at 1 y after TB infection (**Fig. 6**). In contrast, all monkeys in saline group were died within 200 d after TB challenge. Thus, survival rate at one year after TB infection was 0% (0/4).

The proliferation of PBL from the monkeys treated with granulysin-vaccine was augmented compared with that of control (saline treated) monkeys (**Fig. 7**). These results indicated the efficacy of granulysin-vaccine in therapeutic models using monkey. Thus, granulysin-vaccine is effective in the monkey as well as the mouse model of TB.

Efficacy of Ksp37-vaccine in therapeutic models. Ksp37 protein is produced from CTL, Type I helper T cell, γ/δ T cell and NK cell. Ksp37 is composed of 223 amino acids. We analyzed the concentration of Ksp37 in the serum of patients with TB by ELISA. The level of Ksp37 protein in the serum of patients with TB (n = 31) was significantly lower than that of healthy volunteers (n = 60) (p < 0.05) (**Fig. 8**). This is first report suggesting the relation between serum level of Ksp37 and TB disease (**Fig. 8**).

Therefore, we tried to elucidate the in vivo function of Ksp37 protein, especially function as an anti-TB agent in vivo.

In the first step, we have established a Ksp transgenic mouse for the analysis of function in vivo. We measured the CFU number of *M. tuberculosis* in the lung 3 weeks after TB aerosol infection. In Ksp transgenic mice, the CFU number of *M. tuberculosis* was decreased compared with that of wild type control mice (**Fig. 9**). This result indicated the anti-TB effect of Ksp37 in vivo.

These finding suggested that Ksp37 produced from CTL and NK cell functions as an important anti- TB factor in humans and mice.

Discussion

In the present study, we evaluated the potential of three kinds of novel therapeutic vaccines (HSP65-, granulysin- and Ksp37-vaccines) in mouse and monkey models of TB. All of the vaccines showed anti-TB effects in therapeutic models. It is noteworthy that efficacy of novel therapeutic vaccines were demonstrated in monkey models as well as murine models. Thus, this is the leading report of new vaccine against TB. According to our knowledge, only a few therapeutic vaccines against TB have been reported.[14,15] HSP65-vaccine as well as 15K granulysin-vaccine

mice. We measured CFU number of *M. tuberculosis* in the lung four weeks after intravenous injection of TB (5×10^5 /mouse). As shown in **Table 3**, reduction of CFU number was observed in 15K granulysin transgenic mice compared with the normal C57BL/6 mice, indicating the in vivo anti-TB effect of 15K granulysin.

Figure 5. Therapeutic effect of granulysin DNA vaccine on TB-infected (DBA/1) mice DBA/1 mice were infected with H37Rv TB using intratracheal aerosol challenge. One week after challenge of TB, 100 μg of HVJ-Envelope/HSP65 DNA + IL-12 DNA and/or 100 μg of HVJ-Envelope/granulysin DNA were injected i.m. into mice 6 times for 3 weeks. Four weeks after TB challenge, mice were sacrified, and CFUs of TB in the liver were evaluated. G1 vs. G2; p < 0.05; G1 vs. G3; p < 0.05; Student's test.


Figure 6. Therapeutic efficacy (survival) of HVJ-Envelope/15K granulysin DNA vaccine, 365 d after TB infection using cynomolgus monkey models. 5×10^2 M. tuberculosis (Erdman strain) were intratracheally into cynomolgus monkeys as described in Materials and Methods. Four weeks after challenge of TB, 400 μg of HVJ-Envelope/15K granulysin were injected i.m. Six times every two weeks. Survival of monkeys treated with this vaccine were evaluated for 1 y (365 d).

vaccine-treated group, compared with saline-treated group (control group). In addition, it is noteworthy that histopathological improvement was observed in the lung of vaccine-treated monkey (365 d after TB infection). A lot of granulomatous lesions were observed in lung of survived monkey, while a little or no such lesions were observed in lung of saline-treated monkey, which had died of TB within 200 d after TB challenge. Histology of granulomatous lesions observed in this experiment was very similar to human lung TB granuloma by histopathological examinations.

Efficacy of 15K granulysin-vaccine was studied in murine models of TB. We used therapeutic models in this experiment. Furthermore, we examined the synergistic effect of two vaccines (the combination of HSP65- and granulysin-vaccines) in the same therapeutic model. The results indicated the synergistic effect of the combinational vaccination. Therefore, the combination of these therapeutic vaccines might be useful for the development of vaccines against human TB infectious disease. In summary, it was demonstrated that granulysin-vaccine had a therapeutic effect against TB in the mouse and monkey models of TB.

We also elucidated the in vivo function of Ksp37. Ksp37 is expressed in cytotoxic lymphocytes, selectively in the effector subset of CD8+ T cells, CD16+ NK cells and γ/δT cells.[13] Expression of Ksp37 mRNA was closely correlated with good prognosis in ovarian cancer cells and gliomas.[16,17] However, detailed immunological function has not been elucidated yet. We first revealed that the level of Ksp37 protein in the serum of patients with TB was lower than that of healthy volunteer. The result suggested the relation between the serum level of Ksp37 and TB disease. Next, we have established Ksp37 transgenic mice to elucidate the in vivo role of Ksp37 in the defense against the infection of

Table 2. Therapeutic efficacy and Immune responses using IL-2 receptor γ-chain gene disrupted SCID-PBL/hu models

(A)	Therapeutic efficacy	
	Treated	CFU of TB (log)
	(-)	6.03 ± 0.06
	HSP65 DNA + IL-12 DNA vaccine	5.40 ± 0.97
(B)	Immune reponses	human CTL and T cell proliferation
	IL-2 R γ-chain(-/-) SCID PBL-hu	human CTL (+++) human T cell proliferation (+++)
	CB17-SCID PBL-hu	human CTL (+) human Tcell proliferation (+)

Therapeutic efficacy of HVJ-envelope / HSP65DNA + IL-12DNA, using in vivo humanized immune models of IL-2 receptor γ-chain disrupted NOD-SCID mice (SCID-PBL/hu). Groups of animals were treated with 3 times with HVJ-envelope / HSP65DNA + IL-12DNA (50 ug i.m.). Ten days after the third vaccination, mice were sacrificed and CFU of TB in the liver of mice were accessed as described in Materials and Methods. 1×10^7 PBL from a healthy human volunteer were injected i.p. into IL-2 receptorγ-chain disrupted NOD-SCID mice. Twenty one days after injection of PBL, mice were challenged with 5×10^5 H37Rv i.v. and then treated with vaccine. *Student's t-test was used to compare the CFU of TB of each group (p < 0.05). Human immune responses [human CTL activity and human T cell proliferation against alloantigen (CESS cells)] of IL-2 receptor γ-chain (-/-) NOD SCID PBL-hu mice were compared with those of CB17-NOD-SCID PBL-hu mice. (+), weak; (+++), very strong.

delivered by HVJ-Envelope vector prolonged the survival and augmented the immune responses in the cynomolgus monkey model which closely mimics human TB disease. Thus, we are taking advantage of the availability of multiple animal models and are accumulating essential data on the DNA vaccine/HVJ-envelope in anticipation of initiating a phase I clinical trial.

It is very important to evaluate the long-term survival in a monkey model, as human TB is a chronic infection disease. Thus, it is necessary for the development of effective vaccine to evaluate the long-term survival of monkey.[2,3,7-9] In this study, increase in the survival rate was also observed in HVJ-Envelope/15K granulysin

Table 3. In vivo anti-TB effect of 15kDa Granulysin Transgenic mouse

Mouse	Lung Number of *M. tuberculosis* 4 weeks after TB injection (log)
G1 15K Granulysin Tg	5.3 ± 0.35
G2 Wild Type C57BL/6	6.0 ± 0.5

Mean ± SD, n = 7; *p < 0.05 G1 vs. G2; Tukey-Kramer's HSD; In vivo inhibition of the growth of *M. Tuberculosis* in the 15K granulysin transgenic mice; In vivo anti-TB effect of 15K granulysin transgenic mouse; Five 15 K granulysin transgenic mice and five wild type C57BL/6 mice were injected with 5 × 10⁵ H37Rv M. tuberculosis i.v. Four weeks after the challenge of *M. Tuberculosis*, mice were sacrificed. CFU of *M. Tuberculosis* in the lungs of these mice were assessed described in Material and Methods. Student's t-test was used (p < 0.05).

M. tuberculosis. Ksp37 transgenic mice showed in vivo anti TB effect. Thus it was demonstrated that Ksp37 played an important role in anti-TB function in human as well as mice bodies. Finally, we examined the efficacy of Ksp37-vaccine in the mouse model of TB. Similar to granulysin-vaccine, Ksp37-vaccine augmented in vivo differentiation of CTL against TB (data not shown). In addition, simultaneous administration of Ksp37- and granulysin-vaccines induced CTL generation synergistically (data not shown). Therefore, these findings indicate that granulysin- and Ksp37-vaccine might provide very useful weapon as a novel TB vaccine, in the monotherapy or combination therapy.

The HSP65 vaccine showed a significant therapeutic effect against TB, as described previously: (1) Prolongation of survival of mice infected with XDR-TB; (2) Decrease in the CFU of TB in lung, liver and spleen of mice infected with MDR-TB as well as drug-sensitive TB (H37Rv); (3) Decrease in the CFU of TB in organs of mice challenged with TB in the in vivo humanized immune model of SCID-PBL/hu.

Here, we revealed the synergistic effects of the combination therapy of HSP65-vaccine and a first line chemotherapy drug Isoniazid (INH). It is very important to make a suitable regimen, which enables the treatment of the patient with TB to complete within a shorter period. In such circumstances, our data demonstrating the synergistic effect of the combinational therapy using a DNA vaccine and a chemotherapy drug will provide a new strategy for the treatment of TB.

We also revealed the importance of administration route of DNA vaccine. Generally, vaccines are administrated either intradermally (i.d.), intramuscullary (i.m.) or subcutaneously (s.c.). Our data suggested that the intradermal injection is suitable for the administration of our DNA vaccines. Therefore, in the monkey model we plan to conduct the efficacy study of intradermal injection of this vaccine. We will compare the efficacy of intradermal administration to conventional i.m administration.

In the recent study using cynomologus monkeys, it is suggested that i.d. vaccination of HSP65-vaccine showed stronger therapeutic effects against TB than i.m. vaccination on the basis of the prolongation of survival and ESR (Erythrocyte Sedimentation Rate).

DNA vaccine is a relatively new approach of immunization for infectious diseases.[3,4,18-21] We have developed a hemagglutinating

virus of Japan envelope (HVJ-Envelope) using inactivated Sendai virus, as a nonviral vector for drug delivery.[22-24] It can efficiently deliver DNAs, siRNAs, proteins and anti-cancer drugs into cells both in vitro and in vivo.[25-27] Therefore, HVJ-Envelope was suitable as an efficient and safe vector for DNA vaccines.

The priority of development of vaccine(s) to prevent reactivation of TB will be increased, since large proportion of the world is latently infected with TB. The combination of HSP65-vaccine with conventional vaccine (BCG) showed synergistic effects in the mouse and monkey models of TB and prolonged the survival of animals. Therefore, it will be important to evaluate the current vaccines as post-exposure vaccines. Combination of several vaccines or combination of vaccines with drugs for chemotherapy might provide a new insight for the prevention of the reactivation of TB.

In conclusion, our data indicated the synergistic therapeutic effect of combination of HSP65-, granulysin- and Ksp37-vaccines or combination of these DNA vaccines and first line chemotherapy drug(s). Combinational therapy using vaccines and antibiotics might provide novel rationale against MDR-TB therapy. Furthermore, the efficacies of HSP65 vaccine and granulysin vaccine were confirmed in the murine therapeutic model for XDR-TB and cynomolgus monkey therapeutic model. These data will provide a rationale for moving this vaccine into clinical trial. HSP65-, granulysin- and Ksp37-vaccines might be useful vaccines against TB including XDR-TB and MDR-TB after the clinical trials.

Materials and Methods

Methods for the evaluation of the therapeutic efficacy of the vaccine on the *M. tuberculosis*-infected monkeys. Cynomolgus


Figure 7. Proliferation of PBL from monkeys vaccinated with HVJ-Envelope/15K granulysin DNA by the stimulation with HSP65 antigen. 5 × 10² *M. tuberculosis* (Erdman strain) were intratracheally into cynomolgus monkeys as described in Materials and Methods. Four weeks after challenge of TB, 400 μg of HVJ-Envelope/15K granulysin were injected i.m. Six times every two weeks. The proliferation of PBL from monkeys vaccinated with HVJ-Envelope/15K granulysin on 13 weeks after TB challenge were assessed by the ³H-TdR uptake of lymphocyte for 3 d culture.

monkeys were housed in a BL 3 animal facility of the Leonard Wood Memorial Research Center. The animals were vaccinated nine times with the HVJ-envelope with expression plasmid of both HSP65 and human IL-12 (HSP65 + hIL-12/HVJ: 400 ug i.m.), one week after the challenge with the *M. tuberculosis* Erdman strain (5×10^2) by intratracheal instillation. Immune responses and survival were examined as described in our previous studies.[2,6,7]

The animals were vaccinated with HVJ-Envelope/15K granulysin DNA vaccine 6 times. Four weeks after challenge of TB, 400 μg of HVJ-Envelope/15K granulysin were injected i.m. six times every two weeks. Survival of monkeys treated with this vaccine were evaluated. All animal experiments were approved by the Leonard Wood Memorial Animal Care and Use Committee and the National Hospital Organization Kinki-chuo Chest Medical Center Animal Care and Use Committee.

Methods for the evaluation of the efficacy of vaccines on the *M. tuberculosis*-**infected mice.** DNA vaccines encoding *M. tuberculosis* HSP65 and IL-12 were encapsulated into HVJ-Envelope.[3,6,8,28] HVJ-Envelope were prepared as described previously1.[4,29] The HVJ-Envelope complex was aliquoted and stored at -70°C until use. Groups of mice were vaccinated three times with 100 μl of HVJ-Envelope solution containing 50 μg of pcDNA-IgHSP65 and 50 μg of pcDNA-mIL12p40p35-F in the tibia both anterior muscles after TB challenge.[28,29] At 30 d after intravenous challenge of *M. tuberculosis* H37Rv and MDR-TB, the number of CFU in the lungs, spleen, and liver were counted and therapeutic efficacy of HVJ-Envelope DNA vaccines was evaluated.[28,29] DBA/1 mice were treated with HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine three times i.m. at 1, 8 and 15 d after the challenge of 5×10^5 CFU MDR-TB i.v. Therapeutic efficacy was also evaluated by chronic TB infection model of mice using aerosol challenge of TB (15CFU/mouse: Madison aerosol exposure chamber, University of Wisconsin). Mice were maintained in isolator cages, manipulated in laminar flow hoods and used between 8–10 weeks of age. All vaccinations and experiments on isolate tissue of animal were done under anesthetic state with sevoflurane. Infected animals were housed in individual micro-isolator cages in a Biosafety Level (BL) 3 animal facility of the NHO Kinki-chuo Chest Medical Center. All animal experiments were approved by the National Hospital Organization Kinki-chuo Chest Medical Center Animal Care and Use Committee.

Methods for the establishment of SCID-PBL/hu model. IL-2 receptor γ-chain disrupted NOD-SCID-PBL/hu was constructed as described in our previous study.[4,5] CTL activity was assessed using the method as described previously.[30-32]

Methods for the establishment of granulysin transgenic mouse. Either 15K granulysin gene, 9K granulysin gene or secreted 9K granulysin DNA (15K Gra secretory signal DNA was fused into N-terminal of 9K granulysin DNA) were transferred to expressing plasmid DNA (pCAGGS) having CAG promoter. DNA fragment was injected to pronuclei embryo and grafted to 200 foster parents. Two types of 15K granulysin Tg mice, 3 types of 9K granulysin Tg mice and 6 types of secreted 9K granulysin Tg mice were made. Granulysin activity was assessed by monoclonal antibody targeting 15K granulysin and 9K granulysin. *Mycobacterium tuberculosis*


Figure 8. Killer specific secretory protein of 37kDa (Ksp37 protein) in the serum of patients with tuberculosis. Ksp37 protein in the serum of 31 patients with TB and 60 healthy volunteers were assessed by ELISA.


Figure 9. In vivo anti-TB effect of Ksp37 transgenic mice. Ksp37 Tg mice were established as described in Materials and Methods. Ksp37 Tg mice, 15K granulysin Tg mice, 9K graunlysin Tg mice and wild type C57BL/6 mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber.

H37Rv 5×10^5 CFU was intravenously injected to 15K granulysin Tg mice, 9K granulysin Tg mice, wild type (control) mice and normal C57BL/6 mice (8–12weeks).[3,7] From 2 to 12 weeks after injection, these mice were sacrificed. The lungs, the liver and the spleen of these mice were removed, homogenized and cultivated for 14 d on 7H11 agar medium. Then, the number of colony of *Mycobacterium tuberculosis* was measured.[28,29]

Method for the establishment of Ksp37 transgenic mouse. Ksp37 gene were transferred to expressing plasmid DNA (pCAGGS) having CAG promoter. DNA fragment was injected to pronuclei embryo and grafted to 200 foster parents. Two types of Ksp Tg mice (#13, #14) were made. Ksp activity was assessed by monoclonal antibody targeting Ksp 37.

Reagents. Isoniazid (INH) was obtained from Sigma Co. Ltd (lot No. 117K0712). Rifampicin (RFP) was obtained from Sigma

Co. Ltd (lot No. 087K18753). An amount of 0.03 mg/mouse of INH and 0.1 mg/mouse of RFP were administered to mice per os.

Statistical analysis. Student's t tests and Tukey-Krumer's test were used to compare log 10 value of CFU between groups following challenge of TB. Student's t tests were also performed to compare immune responses between groups in T cell proliferation assay. A P-value of < 0.05 was considered significant.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430-6; PMID:8597953; http://dx.doi.org/10.1038/nm0496-430.
2. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132-5; PMID:15755583; http://dx.doi.org/10.1016/j.vaccine.2005.01.057.
3. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine 2007; 25:2990-3; PMID:17280753; http://dx.doi.org/10.1016/j.vaccine.2007.01.014.
4. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335-43; PMID:9102222.
5. Okada M, Okuno Y, Hashimoto S, Kita Y, Kanamaru N, Nishida Y, et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. Vaccine 2007; 25:3038-40; PMID:17289225; http://dx.doi.org/10.1016/j.vaccine.2007.01.032.
6. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009; 27:3267-70; PMID:19200841; http://dx.doi.org/10.1016/j.vaccine.2009.01.064.
7. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Hum Vaccin 2011; 7(Suppl):60-7; PMID:21546794; http://dx.doi.org/10.4161/hv.7.0.14563.
8. Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models. Hum Vaccin 2011; 7(Suppl):108-14; PMID:21263229; http://dx.doi.org/10.4161/hv.7.0.14571.
9. Okada M, Kita Y. Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine. Hum Vaccin 2010; 6:297-308; PMID:20372079; http://dx.doi.org/10.4161/hv.6.4.10172.
10. Peña SV, Hanson DA, Carr BA, Goralski TJ, Krensky AM. Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J Immunol 1997; 158:2680-8; PMID:9058801.

11. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282:121-5; PMID:9756476; http://dx.doi.org/10.1126/science.282.5386.121.
12. Huang LP, Lyu SC, Clayberger C, Krensky AM. Granulysin-mediated tumor rejection in transgenic mice. J Immunol 2007; 178:77-84; PMID:17182542.
13. Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K, et al. A novel serum protein that is selectively produced by cytotoxic lymphocytes. J Immunol 2001; 166:6404-12; PMID:11342666.
14. Rook GAW, Lowrie DB, Hernàndez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 2007; 196:191-8; PMID:17570105; http://dx.doi.org/10.1086/518937.
15. Kaufmann SH, Hussey G, Lambert PH. New vaccine for tuberculosis. Lancet 2010; 375:2110-9; http://dx.doi.org/10.1016/S0140-6736(10)60393-5.
16. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, et al. POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One 2010; 5:e13837; PMID:21079801; http://dx.doi.org/10.1371/journal.pone.0013837.
17. Yamanaka R, Arao T, Yajima N, Tsuchiya N, Homma J, Tanaka R, et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006; 25:5994-6002; PMID:16652150; http://dx.doi.org/10.1038/sj.onc.1209585.
18. Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998; 2:971-8; PMID:9869111.
19. Lowrie DB. DNA vaccines against tuberculosis. Curr Opin Mol Ther 1999; 1:30-3; PMID:11249680.
20. Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008; 372:164-75; PMID:18620952; http://dx.doi.org/10.1016/S0140-6736(08)61036-3.
21. Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine 2007; 25:3742-51; PMID:17321015; http://dx.doi.org/10.1016/j.vaccine.2007.01.112.
22. Saeki K, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8:2133-41; PMID:9414261; http://dx.doi.org/10.1089/hum.1997.8.17-2133.
23. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6:219-26; PMID:12161188; http://dx.doi.org/10.1006/mthe.2002.0647.

24. Kaneda Y. New vector innovation for drug delivery: development of fusigenic non-viral particles. Curr Drug Targets 2003; 4:599-602; PMID:14577648; http://dx.doi.org/10.2174/1389450033490740.
25. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005; 53:307-32; PMID:16240999; http://dx.doi.org/10.1016/S0065-2660(05)53012-8.
26. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7:1044-52; PMID:15756713; http://dx.doi.org/10.1002/jgm.753.
27. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006; 5:1021-8; PMID:16648574; http://dx.doi.org/10.1158/1535-7163.MCT-05-0352.
28. Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine 2006; 24:1191-204; PMID:16216394; http://dx.doi.org/10.1016/j.vaccine.2005.08.103.
29. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. Clin Dev Immunol 2011; 2011:549281; PMID:21437226; http://dx.doi.org/10.1155/2011/549281.
30. Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci U S A 1981; 78:7717-21; PMID:6801660; http://dx.doi.org/10.1073/pnas.78.12.7717.
31. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583-90; PMID:6600487; http://dx.doi.org/10.1084/jem.157.2.583.
32. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141:1543-9; PMID:3261754.

The study of novel DNA vaccines against tuberculosis

Induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis

Masaji Okada,[1,*] Yoko Kita,[1] Toshihiro Nakajima,[2] Satomi Hashimoto,[1] Hitoshi Nakatani,[1] Shiho Nishimatsu,[1] Yasuko Nishida,[1] Noriko Kanamaru,[1] Yasuhumi Kaneda,[3] Yasushi Takamori,[4] David McMurray,[5] Esterlina V. Tan,[6] Marjorie L. Cang,[6] Paul Saunderson[6] and E.C. Dela Cruz[6]

[1]Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan; [2]Ikeda Laboratory; GenomIdea, Inc.; Midorigaoka, Ikeda; [3]Division of Gene Therapy Science; Graduate School of Medicine; Osaka University; Suita, Osaka Japan; [4]Department of Periodontology; Tsurumi University School of Dental Medicine; Tsurumi, Tsurumiku Japan; [5]System Health Center; College of Medicine; Texas A&M University; College Station, TX USA; [6]Leonard Wood Memorial Institute; Cebu, Philippines

Results: HSP65 + IL-12 DNA vaccine showed higher protective efficacy compared with BCG in both mouse and monkey models of TB. It induced the TB-specific CTL in the mouse model of TB, while little level of activity was observed after the injection of BCG. It also showed strong therapeutic efficacy against MDR-TB. In the monkey model, the vaccine augmented the production of IFN-γ and IL-2 from PBL and the therapeutic effect was correlated with the level of IL-2. We next evaluated the potential of DNA vaccine encoding a granulysin, which is an important defensive molecule expressed by human T cells. We found that granulysin-encoding vaccine induced the differentiation of the CTL in vitro and in vivo. It also showed therapeutic efficacy against TB in the monkey as well as the mouse model. The DNA vaccine encoding a Ksp37 also induced the TB-specific CTL in vitro and in vivo in the mouse model. It augmented the production of IL-2, IFN-γ and IL-6 from T cells and spleen cells. A synergistic effect on the activation of the TB-specific CTL was observed by the combination of Ksp37 DNA vaccine with granulysin DNA vaccine.

Purpose and Methods: Emergence of the multi-drug resistant (MDR) Mycobacterium tuberculosis (TB) is a big problem in the world. We have developed novel TB vaccines [DNA vaccines encoding HSP65 + IL-12, granulysin or killer-specific secretory protein of 37kDa (Ksp37)] using Hemagglutinating virus of Japan -envelope (HVJ-E). It is suggested that the activity of the TB-specific CTL is one of the most important factor for the resistance to TB and immunity for TB in chronic human TB disease. Therefore, we examined the level of activation of the TB-specific CTL after the administration of these vaccines.

Conclusion: These data indicate that our novel vaccines (HSP65 + IL-12 DNA, granulysin and Ksp37) have a capability to activate the TB-specific CTL and will be very strong protective and therapeutic vaccines against TB.

Introduction

Tuberculosis is a major global threat to human health, with about 2 million people dying every year from Mycobacterium tuberculosis (TB) infection. The only tuberculosis vaccine currently available is an attenuated strain of Mycobacterium bovis BCG (BCG), although its efficacy against adult TB disease remains controversial. Furthermore, multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant TB (XDR-TB) are becoming big problems in the world. It has been reported that a cytotoxic T-lymphocyte (CTL) is activated during the induction of host protective immune responses to TB.[1-4] In such circumstances, the development of therapeutic vaccine against TB as well as prophylactic vaccine against TB is expected. Therefore, we have recently developed a novel TB vaccine, a DNA vaccine expressing mycobacterial heat shock protein 65 (HSP65) and interleukin-12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-liposome (HSP65 + IL-12/HVJ). This vaccine

HVJ-E : Delivery system/adjuvant for DNA vaccine
(Hemagglutinating Virus of Japan)

-Multiple functions in one delivery system (delivery + adjuvant_
-Adjuvant: induction of NK/CTL + repression of Treg via the activation of DC
-Mechanism: natural immune reaction mediated by RIG-I

Figure 1. HVJ-Envelope exerts strong adjuvant activity by the induction of CTL/NK and repression of regulatory T cells via the activation of dendritic cells.

was 100-fold more efficient than BCG in the murine model on the basis of the elimination of *M. tuberculosis*, which is mediated by the induction of CTL.[1,5,6] Furthermore, the HSP65 + IL-12 vaccine delivered by HVJ-envelope was 10,000-fold more efficient than BCG in the murine TB-prophylactic model. This vaccine induced a strong activity of CTL against TB, while BCG vaccine induced little activity of CTL in the same model. It is considered that CTL is most important lymphoid cells for the immunity to TB in chronic human TB diseases. In the present study, we analyzed CTL activity and IFN-γ production after the vaccination with our vaccines. We also evaluated the prophylactic effect in the cynomolgus monkey and mouse models of TB. A nonhuman primate model of TB is an excellent model of human tuberculosis and provides a lot of information for vaccine development. In fact, we previously evaluated the protective effects of HSP65 + IL-12/HVJ vaccine in the cynomolgus monkey model and obtained a data indicating the synergistic effect of the HSP65 + IL-12/HVJ and BCG injected by a prime-boost method.[5-7] The combination of the two vaccines showed a strong prophylactic efficacy in the monkey model infected with *M. tuberculosis* (100% survival). We have previously obtained a similar data in the monkey model of TB.[5,6,8] In the present study, we examined the production of cytokines (IFN-γ and IL-2) from PBL and revealed the correlation of cytokine levels and efficacy in the monkey model of TB. We also compared the production levels of these cytokines between the combinatorial vaccination

(BCG prime and HSP65+IL12/HVJ vaccine boost) group and BCG vaccination group. We also evaluated the potential of other novel vaccines (DNA vaccines encoding granulysin or Ksp37), which were expected to induce the differentiation of CTL against TB. Granulysin is a protein secreted from T cells and NK cells and has an antibacterial effect on TB. Killer-specific secretory protein of 37 kDa (Ksp37) vaccine also showed anti-TB efficacy mediated by the induction of CTL. Synergistic effect on the activation of CTL in vitro was observed by the simultaneous administration of Ksp37- and granulysin-based vaccines. In the present study, we further demonstrated the correlation of the activation of CTL and the efficacy of these novel vaccines (HSP65 + IL-12/HVJ-E DNA vaccine, granulysin vaccine and Ksp37 vaccine) in the mouse and monkey models.

Results

Induction of CTL by HSP 65+IL-12/HVJ DNA vaccine in the mouse model of TB. The advantage of HVJ-Envelope vector is shown in **Figure 1**. (1) HVJ-Envelope is efficient delivery system and functions as an adjuvant for DNA vaccine, (2) It induces CTL and NK cell, (3) It induces a production of IL-6 which suppresses the regulatory T cell (T reg) and (4) It activates the innate immunity by the stimulation of RIG-I signaling pathway.

Mice were immunized three times with the DNA vaccine using HVJ-Envelope every three weeks. Four weeks after last

immunization, H37Rv M.tuberculosis (M.tb) was challenged. Five weeks after the challenge of M.tb, mice were sacrificed and C.F.U. of M.tb in lung, liver and spleen were accessed as reported previously.[2,9-11] The C.F.U. of lungs in BCG vaccine alone group was decreased in 1 log compared with non-vaccinated mice group. The combination of the DNA vaccine (HSP65 DNA + IL-12) and BCG using prime-boost method enhanced the prophylactic efficacy (more than 10,000-fold) in the mouse model of TB (BCG prime-DNA vaccine boost). This regimen (BCG-prime then DNA vaccine boost) strongly increased the number of IFN-γ producing cells as compared with BCG vaccine alone (Table 1).

CD8⁺ CTLs have been considered as critical effectors of protective immunity to *M. tuberculosis*. This vaccine induced CD8⁺ CTL against TB, whereas a little or no CTL response was observed in either the naive or BCG-vaccinated mice (Figs. 2 and 3). We used HSP65 DNA-transfected syngenic tumor cells as target cells for CTL. This vaccine augmented the induction of CD8⁺ CD4⁻ CTL against target cells in vivo. On the other hand, a little or no CTL response was observed in BCG-vaccinated mice (Figs. 2 and 3).

Furthermore, we revealed that CD8⁺ T cells as well as CD4⁺ T cells were necessary for the prophylactic effficacy of this vaccine. The administration of anti-CD8 antibody or anti-CD4 antibody during the whole immunization period decreased the antibacterial immunity against TB and increased the number of C.F.U in lungs (Table 2). Simultaneous administration of anti-CD8 and anti-CD4 antibodies resulted in the further increase of the number of C.F.U in lungs (Table 2).

T cell activation by HSP 65+IL-12/HVJ DNA vaccine in the monkey model of TB. We used cynomolgus monkeys and prime-boost methods for the evaluation of our vaccines. We immunized monkeys with BCG Tokyo as a prime vaccine, and then immunize them with this vaccine as a boost vaccine. Survival rate of monkeys vaccinated with BCG prime-HSP65+IL-12 DNA boost was 100%. In contrast, survival rate of monkeys vaccinated with BCG alone was 33%. Thus, prime-boost method showed stronger efficacy than the method vaccinated with BCG alone (data not shown).

IFN-γ production from PBL was the highest level in the monkey group immunized with BCG prime-HSP65+IL-12/HVJ DNA vaccine boost (Fig. 4A). The strongest production of IL-2 from PBL was also observed in same group (Fig. 4B). Thus, in monkey as well as in mouse, we demonstrated that the combination of BCG Tokyo as a prime vaccine and the DNA vaccine as a boost vaccine is suitable method to get the prophylactic efficacies against TB. The prime-boost method efficiently induced the TB-specific CTL and also induced the production of IFN-γ and IL-2.

In Japan, BCG Tokyo vaccine is immunized in all infants. Thus it is expected to function as a prime vaccine. Therefore, we need the administration of novel vaccines (boost vaccines) for adults in Japan. We plan to use similar prime-boost method (BCG prime-DNA vaccine boost) in future clinical trial.

Correlation of IL-2 production and the therapeutic efficacy of HSP65+IL-12/HVJ DNA vaccine in the monkey model of TB. This vaccine showed therapeutic efficacy against MDR-TB

Table 1. ELISPOT assay for IFN-γ antigen-specific responses in the spleens of vaccinated mice following stimulation with HSP65 protein

Vaccination (1st/2nd/3rd)	Number of IFN-γ secreting cells/ (10⁶ splenocytes)		
G1	-/-/-	3	±	1
G2	-/-/BCG	13	±	6
G3	DNA*/DNA/DNA	16	±	4
G4	BCG/DNA/DNA	115	±	12

*DNA means HVJ-Envelope/HSP65 DNA+IL-12 DNA vaccine. Spleen cell cultures were stimulated with rHSP65 protein for 20 h. The number of IFN-γ-secreting cells specific for rHSP65 protein per million cells was determined individually by ELISPOT assay. Results are expressed as the mean ± S.D. of 6 wells of 3 mice per group. The statistically significant differences of the G1 (naïve) group compared with the G2 (BCG alone group), G3 (DNA / DNA / DNA) or G4 (BCG / DNA / DNA) were observed (p < 0.01). The statistically significant difference between G2 group and G4 was observed (p < 0.01). The statistically significant difference between G3 group and G4 was observed (p < 0.01).

and XDR-TB as well as drug-sensitive TB in mice.[9,11,12] Therefore, we confirmed the therapeutic efficacy of the DNA vaccine and T cell responses induced by the DNA vaccine in the monkey model of TB. To establish the model of TB, human TB (5 × 10² CFU) was intratracheally instillated in monkeys. After the TB infection, DNA vaccine was injected intramuscularly 9 times, three times a week. Therapeutic effect was evaluated on the basis of survival, ESR, body weight, immune responses, chest X-ray and PPD skin test.

Injection of the therapeutic vaccine improved the survival of monkeys, as compared with the saline (control) group. No death was observed in monkey group treated with HSP65 +IL-12/HVJ DNA vaccine. In contrast, the survival rate of control saline group was 60% (data not shown). The proliferation of PBL after the stimulation with HSP65 was measured to evaluate the immune response. The proliferation of PBL from the monkeys treated with the DNA vaccine was more augmented than that from the monkeys treated with saline (data not shown). IL-2 production from PBL after the stimulation with killed TB H37Ra antigens was also examined. The level of IL-2 was higher in the DNA vaccine-treated group than that in saline control group (Table 3A). In addition, the IL-2 production from PBL after the stimulation with PPD was seemed to correlate with the survival after TB challenge. The level of IL-2 production of died monkeys was significantly lower than that of survived monkeys in saline group at 53days after TB challenge (Table 3B). IL-2 production by the stimulation with HSP65 protein was also extremely low level in died monkeys (data not shown). These data suggested that therapeutic efficacy of this vaccine correlate with the level of IL-2 production.

Induction of CTL by 15K granulysin vaccine. Granulysin is protein especially abundant in CTL and NK cells. It is be classified into two major protein products [15kDa (15K) granulysin and 9kDa (9K) granulysin]. Latter granulysin (9K) exhibits potent cytotoxic activity against a broad panel of microbial targets, including bacteria, fungi and parasites. Granulysin is present in human CD8⁺ (and some CD4⁺) CTLs, NK cells, NKT

Figure 2. Induction of CD8+ CTL specific for HSP65 protein and *M. tuberculosis* by vaccination with HVJ-Envelope/HSP65 DNA+IL-12 DNA. Spleen cells from the naïve, BCG-, and HVJ-Envelope/HSP65 DNA+IL-12 DNA vaccinated mice were obtained eight weeks after the final vaccination. Cytotoxicity was assayed as release of radioactivity from ^{51}Cr-labeled P815 target that had been transfected with HSP65 DNA using conventional ^{51}Cr release assay as described in Materials and Methods.

cells and γ/δ T cells. However, the precise function of 15K granulysin has not yet been elucidated. We found that 15K granulysin was secreted from CD8 positive CTL, could enter into human macrophages and killed *M. tuberculosis* in the cytoplasm of macrophages. Expression of 15K granulysin protein and mRNA in CD8 positive T cells in the patients with Tuberculosis was significantly lower than those in the healthy volunteers. Moreover, the induction of 15K granulysin production after the stimulation with PPD antigen was suppressed in the supernatants of PBL from TB patients (data not shown).

Recombinant 15K granulysin protein enhanced the in vitro induction of human CTL in the MLC culture (Table 4A). In vivo induction of CTL in the spleen was augmented by the administration of recombinant 15K granulyin into C57BL/6 mice (Table 4B). The administration of recombinant 15K granulysin also augmented in vivo induction of CTL in the lymph node and PEC (peritoneal exudate cells) (Table 4B).

Synergistic effect was observed by the combination of recombinant 15K granulysin and IL-6-related DNA vaccine (IL-6+ IL-6 receptor + gp130 DNA vaccine). In vivo induction of CTL specific for HSP65 TB antigen was augmented by the combination of two vaccines (data not shown). Two types of granulysin vaccines (recombinant 15K granulysin and 15K granulysin DNA vaccine) showed strong therapeutic efficacy in the mice infected with TB by aerosol challenge, resulted in the decrease of the number of C.F.U. in the lungs, liver and spleen (data not shown).

The granulysin (15K) has function as a CTL differentiation factor (Fig. 5). It augmented the differentiation of CTL from precursor CTL into effecter CTL. Thus, this is a first report that reveals the novel function of 15K granulysin (inducer of CTL differentiation). Effector CTLs produce 15K granulysin which

induces the differentiation of CTL. Thus, there is a positive feedback loop (or autocrine system) in the regulation of the production of 15K granulysin. Granulysin (15K) might efficiently induce TB-specific CTL and enhance its therapeutic effect against TB infection by means of such a positive feedback loop system (Fig. 5).

CTL induction by Ksp37 vaccine. To investigate the immune function of Ksp37 protein, in vitro CTL induction by the addition of recombinant Ksp37 protein was analyzed in murine system. Splenic T cells from C57BL/6 were cultured with alloantigen (BALB/c spleen cells) in the presence or absence of recombinant Ksp37 for five days.

Induction of in vitro CTL differentiation was observed by the addition of recombinant Ksp37 (Fig. 6), suggesting that Ksp37 has function as a CTL differentiation factor.

IL-2 production from T cells and spleen cells was augmented by the addition of Ksp37 protein (Fig. 7A). Ksp37 also augmented the production of IFN-γ and IL-6 from murine spleen cells in vitro (Fig. 7B and C). Thus, Ksp37 is an inducer of multiple types of cytokines (IFN-γ, IL-2 and IL-6).

In order to study the immune function of Ksp37 in vivo, induction of CTL by the administration of Ksp37 DNA vaccine was investigated in murine system. Augmentation of CTL differentiation in vivo in the PEC was observed by the treatment with Ksp37 DNA vaccine (Fig. 8). Thus, Ksp37 DNA vaccine functioned as an inducer of CTL in vivo as well as in vitro. Furthermore, synergistic effect on the in vitro CTL induction was observed by the simultaneous treatment of Ksp37 and granulysin vaccines (Fig. 9).

Taken together, we established three kinds of novel vaccines and examined their potential in the mouse and monkey models in vitro and in vivo.

We demonstrated that: (1) HSP65+IL-12/HVJ-E DNA vaccine (HSP65 vaccine) had a prophylactic effect against TB. We revealed the induction of CD8+ CTL and CD4+ T cell were required for the protective efficacy of HSP65 vaccine. We also confirmed currently available vaccine (BCG vaccine) induced a little or no TB-specific CTL; (2) We also revealed the 15K granulysin functioned as a cytotoxic T cell differentiation factor (CTL differentiation factor). The production of granulysin is regulated by the positive feedback system. Thus, granulysin-based vaccine might have a strong therapeutic potency against TB, since it is expected to effectively induce TB-specific CTL; (3) We also revealed that Ksp37 acts as a CTL differentiation factor in human and mouse. Ksp37 vaccine augmented the production of IL-2, IFN-γ, and IL-6 from murine T cells and spleen